Data from Pharmawand - Curated by EPG Health - Date added 13 March 2019

Bavarian Nordic A/S announced that it has received information from the FDA that the review of the Company's Biologics License Application (BLA) for the liquid-frozen formulation of the MVA-BN smallpox vaccine will be extended by three months. The BLA was granted a priority review in December 2018, originally targeting a six months review process.

However, the FDA has assessed that due the amount of data submitted during the review phase, the agency now requires more time and has extended the target PDUFA action date to September 2019. The BLA maintains priority review status with the FDA, and thus Bavarian Nordic would still be eligible to receive a Priority Review Voucher when MVA-BN is approved. "The BLA for MVA-BN is unusual as we have already manufactured 28 million doses prior to a full regulatory approval and the development involved generating safety and immunogenicity data from 22 clinical studies. So while the review process has not raised any significant concerns to date, we understand that the MVA-BN BLA is unusually large and that the FDA requires more time to complete the review," said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content